Texas Children’s Center for Vaccine Development has a successful track record of developing and advancing recombinant protein-based vaccines against neglected infections, including the coronaviruses SARS and MERS.
For the last six months, the research team at the Center for Vaccine Development has been using its extensive expertise with these related viruses to 1) forge new strategic global alliances and 2) accelerate the design, process, and evaluation of a vaccine that meets very important criteria.
We are committed to developing safe, low cost, easily administered, and rapidly scalable vaccines for the public good, including low- and middle-income countries.